Needham Reiterates Buy on Immunocore Hldgs, Maintains $81 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Immunocore Holdings (NASDAQ:IMCR) and maintained a price target of $81.
August 09, 2024 | 9:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Immunocore Holdings (NASDAQ:IMCR) and maintained a price target of $81.
The reiteration of a Buy rating and the maintenance of a price target at $81 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100